HLN · Haleon plc
$10.27
-0.96% last session
End-of-day data · close of 2026-10-23
Market cap
$45B
Enterprise value
$53B
Trailing P/E
21.0
Forward P/E
16.6
Dividend yield
2.0%
Beta
0.28
Avg volume
15M
Employees
25K
Daily Change %
-0.96%
5 Days Change
2.37%
10 Days Change
9.85%
30 Days Change
13.83%
60 Days Change
2.07%
Month to Day Change
18.92%
Year to Day Change
4.62%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — HLN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-01-23
Latest call per bank · past 12 months
Barclays
Overweight$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-01-23 | Barclays | Upgrade | Equal-Weight → Overweight | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 68 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 7.4% above the 50-day MA ($9.56).
- bullish: Price vs 200-day MA: Trading 6.1% above the 200-day MA ($9.68).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.12) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($8.64) and high ($11.05).
HLN Price Chart
Loading chart for HLN…
Fundamentals
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
RDY
Dr. Reddy's Laboratories Ltd
$11B -5.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.